WO2006075172A3 - Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2 - Google Patents

Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2 Download PDF

Info

Publication number
WO2006075172A3
WO2006075172A3 PCT/GB2006/000122 GB2006000122W WO2006075172A3 WO 2006075172 A3 WO2006075172 A3 WO 2006075172A3 GB 2006000122 W GB2006000122 W GB 2006000122W WO 2006075172 A3 WO2006075172 A3 WO 2006075172A3
Authority
WO
WIPO (PCT)
Prior art keywords
cftr
interaction
phosphorylation
methods
modulating
Prior art date
Application number
PCT/GB2006/000122
Other languages
French (fr)
Other versions
WO2006075172A2 (en
Inventor
Anil Mehta
Russell Crawford
Kathryn Treharne
Original Assignee
Univ Dundee
Anil Mehta
Russell Crawford
Kathryn Treharne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500607A external-priority patent/GB0500607D0/en
Priority claimed from GB0507463A external-priority patent/GB0507463D0/en
Application filed by Univ Dundee, Anil Mehta, Russell Crawford, Kathryn Treharne filed Critical Univ Dundee
Publication of WO2006075172A2 publication Critical patent/WO2006075172A2/en
Publication of WO2006075172A3 publication Critical patent/WO2006075172A3/en
Priority to GB0715741A priority Critical patent/GB2437681B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Abstract

A method of identifying a compound capable of modulating CFTR/CK2 interaction and/or CFTR phosphorylation by CK2 comprising exposing CFTR and/or CK2 to a test compound and assessing the effect of the test compound on CFTR/CK2 interaction and/or CFTR phosphorylation by CK2. A method of screening for compounds of use in preventing or treating a secretory state or disorder and/or a cancer and/or cystic fibrosis wherein CFTR and/or CK2 is exposed to a test compound and the effect of the test compound on CFTR/CK2 interaction and/or CFTR phosphorylation by CK2 is assessed.
PCT/GB2006/000122 2005-01-13 2006-01-13 Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2 WO2006075172A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0715741A GB2437681B (en) 2005-01-13 2007-08-13 Methods of identifying modulators of CFTR/CK2 interaction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0500607.7 2005-01-13
GB0500607A GB0500607D0 (en) 2005-01-13 2005-01-13 Methods
GB0507463.8 2005-04-13
GB0507463A GB0507463D0 (en) 2005-04-13 2005-04-13 Methods

Publications (2)

Publication Number Publication Date
WO2006075172A2 WO2006075172A2 (en) 2006-07-20
WO2006075172A3 true WO2006075172A3 (en) 2006-09-14

Family

ID=36371733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000122 WO2006075172A2 (en) 2005-01-13 2006-01-13 Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2

Country Status (2)

Country Link
GB (1) GB2437681B (en)
WO (1) WO2006075172A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2441131A (en) * 2006-08-24 2008-02-27 Univ Dundee Modulation of binding of CK2a to NDPK
US9447458B2 (en) * 2011-11-16 2016-09-20 Canon U.S. Life Sciences, Inc. Detection of neighboring variants
WO2023167516A1 (en) * 2022-03-03 2023-09-07 숙명여자대학교 산학협력단 Novel 2-(phenylamino)pyridine-based tead inhibitor and pharmaceutical composition comprising same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005273A1 (en) * 1990-09-18 1992-04-02 The Regents Of The University Of Michigan Gene therapy for cystic fibrosis
US20010041685A1 (en) * 2000-01-31 2001-11-15 Yuhong Zhou Mucin synthesis inhibitors
US6620795B1 (en) * 1991-12-17 2003-09-16 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
WO2003087389A2 (en) * 2002-04-08 2003-10-23 Genesegues, Inc. Biologic modulations with nanoparticles
US20040121968A1 (en) * 2002-12-23 2004-06-24 Alexander Ljubimov Antiangiogenesis by inhibiting protein kinase CK2 activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005273A1 (en) * 1990-09-18 1992-04-02 The Regents Of The University Of Michigan Gene therapy for cystic fibrosis
US6620795B1 (en) * 1991-12-17 2003-09-16 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
US20010041685A1 (en) * 2000-01-31 2001-11-15 Yuhong Zhou Mucin synthesis inhibitors
WO2003087389A2 (en) * 2002-04-08 2003-10-23 Genesegues, Inc. Biologic modulations with nanoparticles
US20040121968A1 (en) * 2002-12-23 2004-06-24 Alexander Ljubimov Antiangiogenesis by inhibiting protein kinase CK2 activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOWELL L DANIEL ET AL: "ATP hydrolysis by a CFTR domain: Pharmacology and effects of G551D mutation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 271, no. 2, 10 May 2000 (2000-05-10), pages 518 - 525, XP002382630, ISSN: 0006-291X *
MENDES F ET AL: "Antibodies for CFTR studies", JOURNAL OF CYSTIC FIBROSIS, ELSEVIER, vol. 3, August 2004 (2004-08-01), pages 69 - 72, XP004556432, ISSN: 1569-1993 *
SCOTT-WARD T S ET AL: "Direct block of the cystic fibrosis transmembrane conductance regulator Cl- channel by niflumic acid.", MOLECULAR MEMBRANE BIOLOGY, vol. 21, no. 1, 2004, pages 27 - 38, XP009066980, ISSN: 0968-7688 *

Also Published As

Publication number Publication date
WO2006075172A2 (en) 2006-07-20
GB2437681B (en) 2009-10-21
GB0715741D0 (en) 2007-09-19
GB2437681A (en) 2007-10-31

Similar Documents

Publication Publication Date Title
EP1951364A4 (en) Method and apparatus for analyte data telemetry
NO20051674D0 (en) Method and apparatus for painting the condition of stable structures
FI20055596A (en) Data sheet and method for producing the data sheet
GB0602197D0 (en) Apparatus and methods for seismic streamer positioning
SG118408A1 (en) Methods of monitoring the concentration of an analyte
TW200716624A (en) Compounds for modulating TRPV3 function
HK1132330A1 (en) Systems and methods for performing measurements of one or more analytes comprising using magnetic particles and applying a magnetic field
DE502006005765D1 (en) Detection and device for the detection of recording media
ZA200806515B (en) Method for determining the identity or non-identity and concentration of a chemical compound in a medium
GB0802676D0 (en) Image reproduction apparatus using image files related to an electronic map, imge reproduction method for the same, and recording medium for recording program
EP1723641A4 (en) Hologram recording medium, and recording apparatus and reproducing apparatus for the same
TW200700902A (en) Photosensitive composition containing organic fine particle
SG126806A1 (en) Optical recording medium, recording/reproducing apparatus and method, and recording medium storing program for executing the method
WO2006075172A3 (en) Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
DE602006020114D1 (en) METHOD AND DEVICE FOR ACTIVATING THE POWER SAVINGS WHEN NO DATA WILL BE TRANSMITTED OVER A LOGICAL MEDIA CHANNEL
FI20055704A (en) Method and apparatus for degassing the coating material
WO2007067809A3 (en) Methods of identifying agents that modulate mitochondrial function
EP1952237A4 (en) Apparatus and method for analysis of optical storage media
DE502005002994D1 (en) Method and apparatus for determining the concentrations of at least two ligands
ATE506446T1 (en) METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS
WO2010019811A3 (en) Methods for screening for modulators of ccrl2
FI20041309A0 (en) Method and apparatus for drying solids and mixtures thereof
EP1852860A4 (en) Optical recording medium and method for manufacturing same, substrate and use thereof, and stamper and method for manufacturing same
FI20045423A (en) Method and apparatus for drying fuel
EP1743331A4 (en) Hologram recording medium and apparatus for and method of recording data on the recording medium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 0715741.5

Country of ref document: GB

122 Ep: pct application non-entry in european phase

Ref document number: 06700693

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6700693

Country of ref document: EP